38 results about "CD117" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention relates to a nano antibody targeting CD117 and application of the nano antibody. The invention also relates to a CD117-targeting antibody or an antigen binding fragment thereof and an application of the CD117-targeting antibody or the antigen binding fragment thereof.

The present invention relates to a CD117 antibody and a delivery vector using same, such as lipid nanoparticles (LNPs). Further provided in the present invention are a method for delivering a bioactive substance to CD117+ cells by using the delivery vector and a method for preparing such a lipid nanoparticle conjugate.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.

This application relates to a nanobody targeting CD117 and its application. This application also relates to an antibody targeting CD117 or its antigen-binding fragment and its application.

The present invention relates to CD117 targeted LNP molecules for delivery of pro-apoptotic mRNA to hematopoietic stem cells (HSCs) and methods of use thereof for preconditioning a subject for hematopoietic stem cell therapy or to deplete the subject's HSC population for the treatment of a disease or disorder.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The invention belongs to the technical field of immunological detection, and discloses an antibody composition for detecting early precursor acute T-cell lymphocytes, which comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD99 antibody, a CD4 antibody, a CD34 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD117 antibody, a CD13 antibody, a CD11b antibody, a CD7 antibody, a CD64 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a TdT antibody, an MPO antibody, a CD10 antibody, a CD1a antibody, a cCD3 antibody, a CD7 antibody, a CD19 antibody, a cCD22 antibody and a CD45 antibody; each antibody is a monoclonal antibody marked with a detection marker. The antibody composition can be used for rapidly, accurately and comprehensively detecting early-stage precursor T cell acute lymphocytes at one time.

To provide acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.SOLUTION: There is provided an isolated immunoresponsive cell comprising (a) a first chimeric receptor comprising an extracellular antigen-binding domain that binds to a first antigen, and (b) a second chimeric receptor comprising an extracellular antigen-binding domain that binds to a second antigen, wherein each antigen is selected from a group consisting of FLT3, CD33, CLEC12A, MS4A3, VSTM1, LAT2, MLC1, CD131, GAPT, PRAM1, SLC22A16, SLC17A9, SPNS3, ADGRE2, IL3RA, CD117, CD93, IL1RAP, CD244, CCR1, LILRB2, PIEZO1, CD38, EMB, MYADM, LILRA2, CD300LF, and CD70, and wherein the first antigen is different from the second antigen.SELECTED DRAWING: Figure 1

The invention provides an antibody composition for detecting AML (acute myeloid leukemia) accompanied with CBF beta MYH11. The antibody composition comprises CD2, CD34, CD117, CD64, CD14, CD33, HLA-DR (human leukocyte antigen-DR), CD15, CD11b, CD13, CD38 and CD45 antibodies. During detection, the antibody composition is divided into two types of antibody combinations according to detection targets, and then samples are respectively added for flow cytometry detection; when the proportion of original myeloid cells / nucleated cells is between 6% and 78%, the proportion of mononuclear cells / nucleated cells is greater than 22%, and the proportion of CD2 / mononuclear cells is greater than 20%, determining that the sample is AML with CBF beta MYH11. The method provided by the invention is simple and low in cost, can be used for judging whether the AML patient has CBF beta MYH11 positive or not without further molecular biological PCR (Polymerase Chain Reaction) screening, and has a great practical value.

Among the various aspects of the present disclosure is the provision of conditioning agents for use in allogeneic hematopoietic stem cell transplantation. An aspect of the present disclosure provides for a method of treating a subject or inhibiting alloreactivity in the host-versus-graft direction comprising administering a combination of conditioning agents comprising an anti-body-drug conjugate (ADC) and a JAK1 / JAK2 inhibitor for use in allogeneic hematopoietic stem cell transplantation in an amount sufficient to permit engraftment of allogeneic bone marrow. In some embodiments, the ADC is selected from CD45-SAP, cKit-SAP, CD117-Amanitin, and CD45-PBD. In some embodiments, the JAK1 / JAK2 inhibitor is selected from baricitinib and ruxolitinib. In some embodiments, the method further comprises administering a cancer therapeutic.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Provided are an anti-human CD117 nanobody and use thereof. The nanobody comprises at least one VHH chain. The VHH chain comprises a CDR1, a CDR2, and a CDR3. The amino acid sequence of the CDR1 is set forth in SEQ ID NO: 4, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 5, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 6; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 7, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 8, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 9; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 10, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 11, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 12. The use is use of the nanobody and a formulation thereof in the preparation of a drug for treating thalassemia. The nanobody has a good binding ability to CD117, and has the advantages of small molecular weight, high binding activity, low immunogenicity, easy modification, etc.

This invention relates to an antibody composition, kit, and system for rapid screening of acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies, and a third group of antibodies. The first group of antibodies comprises antibodies against CD71, CD33, CD117, CD34, HLA-DR, CD19, CD10, CD7, and CD45. The second group of antibodies comprises antibodies against CD38, CD56, CD16, CD34, CD13, CD11b, CD64, CD15, and CD45. The third group of antibodies comprises antibodies against CD9, MPO, CD117, and CD45. Each of the antibodies is a monoclonal antibody labeled with a detection marker. The antibody composition contains a cell population targeting the CD117+CD33+ region, and includes three groups of antibodies that recognize acute promyelocytic leukemia, including CD33, CD34, CD64, CD13, CD9, and MPO. Using this antibody composition, acute promyelocytic leukemia can be detected quickly and easily with high sensitivity, specificity, and accuracy. It can accurately and rapidly identify patients with acute promyelocytic leukemia, enabling early diagnosis and treatment.

The application provides a cell identification kit and a use method and application thereof in identifying mast cells, and relates to the technical field of cell identification. The cell identification kit comprises CD117 antibody conjugated magnetic microparticles, CD16 antibody conjugated magnetic microparticles and Fc epsilon R1 alpha antibody conjugated magnetic microparticles, and FcR blocking agent and eluent. The cell identification kit can be used to identify one or more of CD117, Fc epsilon R1 alpha and CD16 on the surface of cells, and target cells with a purity of at least 90% can be obtained. The application is applied to identifying whether a cell is CD117 + Fc epsilon R1 alpha + CD16 ‑ mast cells, target cells with a purity higher than 95% can be obtained, the degranulation rate of mast cells is improved, and the technical problem of a low degranulation rate of mast cells obtained by a mast cell identification method in the prior art is solved.

Compositions and methods for non-genotoxic monoclonal antibody (mAb) conditioning, where the methods involve altering a cluster of differentiation 117 (CD117; c-KIT) polynucleotide sequence in a hematopoietic stem cell (HSC) or progenitor thereof to encode a CD117 polypeptide with reduced binding to the antibody. In various embodiments, the methods further include introducing a therapeutic alteration to a gene of the HSC or progenitor thereof for treatment of a hemoglobinopathy.

Single domain antibody fragments binding to CD117 and lipid nanoparticle conjugates associated with the antibodies and cargos of interest (e.g., a gene editing system). Also provided herein are methods of delivering the cargos to CD117+ cells using the lipid nanoparticle conjugates and methods of preparing such lipid nanoparticle conjugates.

The invention provides a separation and preparation method of dental pulp stem cells. The method comprises the following steps: using dental stem cells (DSC) separated from dental pulp tissues of human permanent teeth or deciduous teeth; obtaining a single-cell suspension through a double-enzyme digestion method; washing the single-cell suspension and the phosphoric acid buffer salt solution with the same volume for three times; carrying out adherent culture on the undigested tissues; culturing in an improved MEM culture medium (MEM-alpha) supplemented with fetal calf serum (FBS) with the volume fraction of 20%, penicillin with the volume fraction of 100 g / ml and streptomycin with the volume fraction of 100 g / ml in an incubator at the temperature of 37 DEG C under the condition of 5% CO2; according to the double-enzyme digestion method, the culture medium is replaced every two days; the culture medium is replaced once every 4-5 days by the tissue adherence method; after 90% confluence is achieved, performing trypsin digestion to harvest adherent cells; under the condition, the content of CD117 positive cells exceeds 96.67%. The dental pulp stem cells obtained by the method do not induce premature differentiation of cells, the cell proliferation speed is greatly increased, more sufficient nutrition is provided for the cells, synthesis of protein is promoted, proliferation of the cells is promoted, and differentiation of the cells is inhibited; the separation speed and the separation effect are improved, and the operation difficulty is also reduced. By utilizing the method disclosed by the invention, a rapid and stable separation method and an efficient amplification system can be established, and the method has a very wide clinical application prospect in the fields of life science and medicine. Along with continuous development of research, hDPSCs can play a greater role in the medical field.

The present disclosure provides for engineered protein constructs, compositions, and uses thereof for treating diseases. The engineered protein constructs and compositions comprising a first antigen-binding moiety that binds Sialic acid–binding immunoglobulin-like lectin 8 (SIGLEC-8) and a second antigen-binding moiety that binds CD117.

The invention discloses an antibody composition for screening CAR-T (Chimeric Antigen Receptor T) treatment AML (acute myeloid leukemia) target spots and application of the antibody composition. The antibody composition comprises a CD38 antibody, a CD371 antibody, a CD34 antibody, a CD117 antibody, a CD123 antibody, a CD33 antibody, a CD133 antibody and a CD45 antibody. When a sample to be detected is detected by adopting the antibody composition disclosed by the invention, malignant cell populations can be positioned and recognized more accurately, so that the antibody composition can be used for quickly and accurately screening CAR-T treatment AML (acute myeloid leukemia) targets, discovering signs of disease recurrence earlier and providing more information about disease prognosis; and doctors and patients are helped to better understand disease progresses and possible results.

This application is directed to methods and compositions related to the treatment and diagnosis of adenocarcinomas, such as adenoid cystic carcinoma (ACC). The methods and compositions related to the use of CD49f, TP63, and / or KIT / CD117 cell-surface markers for subtyping the cancer cells. One method involves using a retinoic acid receptor / retinoid-X receptor inhibitor to inhibit the differentiation of myoepithelial-like cells into ductal-like cells. Another method involves using a retinoic acid receptor / retinoid-X receptor inhibitor to selectively reduce the viability of ductal-like cells.

Engineered nanoparticles for genetic therapies in human blood cells are described and can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases. Targeting of human stem cells is achieved through the binding of CD133, CD117, CD90, with linked targeting moieties that result in rapid internalization of the engineered nanoparticles following binding.

The present disclosure discloses a genetic cassette (100) including one or more promoters (103), and one or more genes disposed downstream of the one or more promoters (103). The one or more genes including at least one of one or more first genes (110) encoding for a single chain variable fragment (scFv) each, and one or more second genes (120) encoding for a ligand each. The scFv is at least one of anti-CD3scFv and anti-CD34scFv. The ligand is at least one of CD38, CD70, CD71, CD80, CD90, CD117, CD252, and CD275.

The present disclosure discloses a genetic cassette (100) including one or more promoters (103), and one or more genes disposed downstream of the one or more promoters (103). The one or more genes including at least one of one or more first genes (110) encoding for a single chain variable fragment (scFv) each, and one or more second genes (120) encoding for a ligand each. The scFv is at least one of anti-CD3scFv and anti-CD34scFv. The ligand is at least one of CD38, CD70, CD71, CD80, CD90, CD117, CD252, and CD275.

To provide a method for depleting hematopoietic stem cells of a subject, and a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy.SOLUTION: This invention provides a method for depleting a subject's hematopoietic stem cells that includes administering to the subject an effective amount of a radiolabeled antibody against CD34, CD117, or CD135, where preferred radiolabels include 131I and 225Ac. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy, where the method includes (i) administering to the subject an amount of the radiolabeled antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.